Valuation : Moberg Pharma AB

Market Cap 531M 55.22M 47.63M 44.87M 40.88M 76.42M 5.22B 76.99M 206M 2.67B 207M 203M 8.76B P/E 2026 *
-28.2x
P/E 2027 * 56.3x
Enterprise Value 531M 55.22M 47.63M 44.87M 40.88M 76.42M 5.22B 76.99M 206M 2.67B 207M 203M 8.76B EV / Sales 2026 *
21.6x
EV / Sales 2027 * 9.45x
Free-Float
84.65%
Yield 2026 *
-
Yield 2027 * -
1 day-0.44%
1 week+6.31%
Current month+2.87%
1 month+18.14%
3 months+14.14%
6 months+14.60%
Current year+11.59%
1 week 10.34
Extreme 10.34
11.46
1 month 9.25
Extreme 9.25
12
Current year 8.5
Extreme 8.5
14.12
1 year 7.53
Extreme 7.53
14.12
3 years 6.15
Extreme 6.15
40.9
5 years 6.15
Extreme 6.15
75.5
10 years 6.15
Extreme 6.15
861
Manager TitleAgeSince
Chief Executive Officer 46 2019-05-14
Director of Finance/CFO 48 2014-12-31
Chief Tech/Sci/R&D Officer - 2026-08-10
Director TitleAgeSince
Director/Board Member 57 2025-05-21
Director/Board Member 44 2025-05-21
Director/Board Member 56 2024-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
7/7/26 Free

Chief Executive Officer

19,693 0.0404%
7/7/26 Free

General Counsel

11,816 0.0243%
7/7/26 Free

Chief Financial Officer

11,201 0.0230%
Change 5-day change 1-year change 3-year change Capi.($)
+1.78%+6.31%+41.05%+51.79% 55.38M
+0.03%-2.06%+58.46%+108.70% 1,034B
+1.32%+1.97%+54.63%+71.35% 654B
-0.36%-1.23%+22.53%+77.73% 459B
+0.49%-5.19%+33.28%+35.53% 343B
+0.27%+3.26%+29.76%+47.50% 307B
+0.12%-2.11%+0.60%+12.03% 251B
-0.03%-0.39%+52.88%+72.68% 237B
+2.64%-1.08%-15.85%-53.97% 202B
-0.32%+0.97%+32.66%+98.94% 186B
Average +0.40%-2.07%+31.00%+52.23% 367.16B
Weighted average by Cap. +0.43%-3.31%+38.83%+67.88%

Financials

2026 *2027 *
Net sales 24.6M 2.56M 2.21M 2.08M 1.89M 3.54M 242M 3.57M 9.55M 123M 9.6M 9.39M 406M 56.2M 5.84M 5.04M 4.75M 4.33M 8.08M 552M 8.14M 21.81M 282M 21.93M 21.45M 927M
Net income -17.3M -1.8M -1.55M -1.46M -1.33M -2.49M -170M -2.51M -6.71M -86.84M -6.75M -6.6M -285M 9.4M 977K 843K 794K 723K 1.35M 92.29M 1.36M 3.65M 47.19M 3.67M 3.59M 155M
Net Debt - -
Logo Moberg Pharma AB
Moberg Pharma AB (publ), formerly Moberg Derma AB (publ) is a Sweden-based pharmaceutical company. The Company is a pharmaceutical company in dermatology focused on the commercialization of proprietary drugs based on proven substances. Moberg Pharma AB (publ) develops MOB-015, the treatment of nail fungus. Its product portfolio includes products for the treatment of skin diseases, pain, the treatment of nails damaged by fungus or psoriasis, dry and damaged feet and range of products for several types of skin and scalp problems. The Company deals with development, manufacture, direct and indirect sale, marketing and licensing of pharmaceuticals, medical devices and skin care products as well as related activities.
Employees
5
Date Price Change Volume
26-09-02 SEK 11.46 +1.78% 56,195
26-09-01 SEK 11.26 +1.08% 16,787
26-08-31 SEK 11.14 +2.01% 45,708
26-08-28 SEK 10.92 +3.02% 32,676
26-08-27 SEK 10.60 -1.67% 41,764
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB

Quarterly revenue - Rate of surprise